Clinical characteristics of TMA cHL patients and correlations with bcl11A immunohistochemical expression on reactive cells
| Characteristic . | n (%) . | BCL11A IHC score . | P . | |
|---|---|---|---|---|
| ≤ 2 . | > 2 . | |||
| Age | ||||
| < 45 y | 121 (84) | 49 | 59 | NS |
| ≥ 45 y | 23 (16) | 11 | 10 | |
| Sex | ||||
| Male | 82 (56.2) | 40 | 36 | NS |
| Female | 64 (43.8) | 21 | 34 | |
| Histologic subtype | ||||
| Nodular sclerosis | 106 (78.5) | 40 | 55 | |
| Mixed cellularity | 26 (19.3) | 14 | 11 | |
| Lymphocyte depletion | 2 (1.5) | 2 | 0 | |
| Unclassified | 1 (0.7) | 0 | 0 | |
| EBV tumor status | ||||
| Negative | 115 (79.3) | 51 | 56 | NS |
| Positive | 30 (20.7) | 10 | 14 | |
| Ann Arbor stage | ||||
| 1 | 9 (6.2) | 0 | 8 | .024 |
| 2 | 77 (52.7) | 31 | 38 | |
| 3 | 29 (19.9) | 13 | 13 | |
| 4 | 31 (21.2) | 17 | 11 | |
| B symptoms | ||||
| Absent | 69 (58.5) | 21 | 43 | NS |
| Present | 49 (41.5) | 23 | 20 | |
| Bulky tumor | ||||
| Absent | 70 (59.8) | 20 | 42 | .002 |
| Present | 47 (40.2) | 28 | 15 | |
| Extranodal extension | ||||
| Absent | 98 (83.8) | 34 | 55 | NS |
| Present | 19 (16.2) | 11 | 7 | |
| No. of nodal sites involved | ||||
| < 3 | 67 (52.3) | 23 | 37 | NS |
| ≥ 3 | 61 (47.7) | 27 | 27 | |
| Inguinal involvement | ||||
| Absent | 88 (90.7) | 30 | 49 | NS |
| Present | 9 (9.3) | 7 | 2 | |
| ESR | ||||
| < 50 | 64 (52) | 25 | 37 | NS |
| ≥ 50 | 59 (48) | 24 | 25 | |
| Hemoglobin | ||||
| < 10.5 g/dL | 29 (21.5) | 14 | 12 | NS |
| ≥ 10.5 g/dL | 106 (78.5) | 40 | 56 | |
| White cell count | ||||
| ≤ 15 × 109/L or less | 110 (80.3) | 43 | 57 | NS |
| > 15 × 109/L | 27 (19.7) | 12 | 11 | |
| Lymphocyte count | ||||
| < 0.6 × 109/L or < 8% | 22 (17.5) | 12 | 5 | .033 |
| ≥ 0.6 × 109/L or ≥ 8% | 104 (82.5) | 39 | 60 | |
| Albumin | ||||
| < 40 g/L | 56 (53.8) | 28 | 20 | .037 |
| ≥ 40 g/L | 48 (46.2) | 16 | 30 | |
| International Prognostic Score | ||||
| IPS ≤ 2 | 60 (47.6) | 16 | 39 | .003 |
| IPS > 2 | 66 (52.4) | 35 | 25 | |
| Outcome | ||||
| Favorable | 74 (51) | 8 | 53 | < .001 |
| Unfavorable | 71 (49) | 53 | 17 | |
| Characteristic . | n (%) . | BCL11A IHC score . | P . | |
|---|---|---|---|---|
| ≤ 2 . | > 2 . | |||
| Age | ||||
| < 45 y | 121 (84) | 49 | 59 | NS |
| ≥ 45 y | 23 (16) | 11 | 10 | |
| Sex | ||||
| Male | 82 (56.2) | 40 | 36 | NS |
| Female | 64 (43.8) | 21 | 34 | |
| Histologic subtype | ||||
| Nodular sclerosis | 106 (78.5) | 40 | 55 | |
| Mixed cellularity | 26 (19.3) | 14 | 11 | |
| Lymphocyte depletion | 2 (1.5) | 2 | 0 | |
| Unclassified | 1 (0.7) | 0 | 0 | |
| EBV tumor status | ||||
| Negative | 115 (79.3) | 51 | 56 | NS |
| Positive | 30 (20.7) | 10 | 14 | |
| Ann Arbor stage | ||||
| 1 | 9 (6.2) | 0 | 8 | .024 |
| 2 | 77 (52.7) | 31 | 38 | |
| 3 | 29 (19.9) | 13 | 13 | |
| 4 | 31 (21.2) | 17 | 11 | |
| B symptoms | ||||
| Absent | 69 (58.5) | 21 | 43 | NS |
| Present | 49 (41.5) | 23 | 20 | |
| Bulky tumor | ||||
| Absent | 70 (59.8) | 20 | 42 | .002 |
| Present | 47 (40.2) | 28 | 15 | |
| Extranodal extension | ||||
| Absent | 98 (83.8) | 34 | 55 | NS |
| Present | 19 (16.2) | 11 | 7 | |
| No. of nodal sites involved | ||||
| < 3 | 67 (52.3) | 23 | 37 | NS |
| ≥ 3 | 61 (47.7) | 27 | 27 | |
| Inguinal involvement | ||||
| Absent | 88 (90.7) | 30 | 49 | NS |
| Present | 9 (9.3) | 7 | 2 | |
| ESR | ||||
| < 50 | 64 (52) | 25 | 37 | NS |
| ≥ 50 | 59 (48) | 24 | 25 | |
| Hemoglobin | ||||
| < 10.5 g/dL | 29 (21.5) | 14 | 12 | NS |
| ≥ 10.5 g/dL | 106 (78.5) | 40 | 56 | |
| White cell count | ||||
| ≤ 15 × 109/L or less | 110 (80.3) | 43 | 57 | NS |
| > 15 × 109/L | 27 (19.7) | 12 | 11 | |
| Lymphocyte count | ||||
| < 0.6 × 109/L or < 8% | 22 (17.5) | 12 | 5 | .033 |
| ≥ 0.6 × 109/L or ≥ 8% | 104 (82.5) | 39 | 60 | |
| Albumin | ||||
| < 40 g/L | 56 (53.8) | 28 | 20 | .037 |
| ≥ 40 g/L | 48 (46.2) | 16 | 30 | |
| International Prognostic Score | ||||
| IPS ≤ 2 | 60 (47.6) | 16 | 39 | .003 |
| IPS > 2 | 66 (52.4) | 35 | 25 | |
| Outcome | ||||
| Favorable | 74 (51) | 8 | 53 | < .001 |
| Unfavorable | 71 (49) | 53 | 17 | |